Director, Medicinal Chemistry (Small Molecule, Kinase Inhibitor)
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers.
The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in small cell lung cancer (SCLC) and triple negative breast cancer (TNBC).
These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone.
Position Summary:
Under the direction of the CSO, this position will lead our chemistry efforts. This position will be responsible for leading new project medicinal chemistry efforts as well as supporting our late-stage drug development program as needed.
Job Responsibilities:
Qualifications:
Salary range of $180-285k. This is a San Diego based, on-site position.
Seniority level: Director
Employment type: Full-time
Job function: Science, Research, and Project Management
Industries: Biotechnology Research and Pharmaceutical Manufacturing